Physicochemical Properties
Molecular Formula | C22H19NO5 |
Molecular Weight | 377.3900 |
Exact Mass | 377.126 |
CAS # | 28342-31-6 |
Related CAS # | 28342-31-6 |
PubChem CID | 5317235 |
Appearance | White to yellow solid |
Density | 1.5±0.1 g/cm3 |
Boiling Point | 563.7±50.0 °C at 760 mmHg |
Melting Point | 210-212℃(ethanol) |
Flash Point | 169.0±27.3 °C |
Vapour Pressure | 0.0±1.5 mmHg at 25°C |
Index of Refraction | 1.724 |
LogP | 4.45 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Heavy Atom Count | 28 |
Complexity | 589 |
Defined Atom Stereocenter Count | 0 |
SMILES | O(C([H])([H])C([H])([H])[H])C1([H])C2C3=C(C([H])=C([H])C=2C2C([H])=C([H])C4=C([H])C5=C(C([H])=C4C=2N1C([H])([H])[H])OC([H])([H])O5)OC([H])([H])O3 |
InChi Key | FCEXWTOTHXCQCQ-UHFFFAOYSA-N |
InChi Code | InChI=1S/C22H19NO5/c1-3-24-22-19-13(6-7-16-21(19)28-11-25-16)14-5-4-12-8-17-18(27-10-26-17)9-15(12)20(14)23(22)2/h4-9,22H,3,10-11H2,1-2H3 |
Chemical Name | 23-ethoxy-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21)-octaene |
Synonyms | Ethoxysanguinarine |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | CIP2A; Apoptosis |
ln Vitro |
Ethoxysanguinarine has an IC50 of 9.37 μM (for SW480 cells), 7.19 μM (for HCT116 cells), 6.55 M (for HT69 cells), and 3.57 μM (for SW620 cells)[1]. Ethoxysanguinarine (3 μM or 5 μM, 24 h) down-regulates phospho-Akt and reduces CIP2A/PP2A/Akt pathway expression in the SW620 and HT29 cells[1]. Ethoxysanguinarine (3 μM or 5 μM, 24 h) increases PP2A activity and prevents phosphorylation of the protein kinase B downstream of CIP2A. [1]. Ethoxysanguinarine (1-3 μM or 4.5-5 μM, 24 h) decreases CIP2A transcription (protein level) and induces CIP2A proteolysis in the SW620 and HT29 cells[1]. |
ln Vivo | Ethoxysanguinarine (0.5 mg/kg; s.c.; 5 times per week; 4 weeks) inhibits the development of colorectal cancer (CRC) xenograft tumors in mice[1]. |
References |
[1]. Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer cells by inhibiting CIP2A. Int J Oncol. 2018 Mar 16. |
Solubility Data
Solubility (In Vitro) |
DMSO: ~60 mg/mL (159.0 mM) H2O: < 0.1 mg/mL |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.51 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6498 mL | 13.2489 mL | 26.4978 mL | |
5 mM | 0.5300 mL | 2.6498 mL | 5.2996 mL | |
10 mM | 0.2650 mL | 1.3249 mL | 2.6498 mL |